Gunawan AS, McLornan DP, Wilkins B, Waghorn K, Hoade Y, Cross NCP, Harrison CN. Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia. Haematologica [Internet]. 2017May31 [cited 2026Nov.11];102(6):e238-e240. Available from: https://haematologica.org/article/view/8117